Valeant Pharmaceuticals has slammed Allergan’s attempt to market a generic version of its Relistor (methylnaltrexone bromide) drug.
If you are already subscribed please login.
Official LSIPR subscribers include:
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Valeant; Allergan; ANDA; Relistor; US District Court for the District of New Jersey